Scheen A J
Université de Liège, Service de Diabetologie, Nutrition et Maladies métaboliques et Service de Médecine interne générale, Département de Médecine, CHU Sart Tilman.
Rev Med Liege. 2003 Oct;58(10):641-5.
Gliclazide modified release that has been recently launched by Servier (Uni Diamicron 30 mg) is a new formulation of gliclazide to be given once daily. The original hydrophilic matrix improves the biodisponsibility of gliclazide and allows a progressive release of the drug that better parallels the 24-hour glycaemic profile of patients with type 2 diabetes mellitus. Such characteristics may explain the rather low risk of hypoglycaemic episodes and the morning administration should contribute to improve patient's compliance. As the common formulation of gliclazide, the modified release formulation is indicated in the treatment of type 2 diabetes, in adult subjects, when diet, exercise and weight loss are insufficient to restore an adequate metabolic control. It may be used alone or in combination with metformin, glitazones, acarbose or insulin, with the same general principles of use as for the classical formulation of gliclazide.
施维雅公司最近推出的格列齐特缓释片(达美康缓释片30毫克)是一种每日服用一次的格列齐特新剂型。其原有的亲水性基质提高了格列齐特的生物利用度,并使药物能够逐渐释放,更好地与2型糖尿病患者的24小时血糖曲线相匹配。这些特性可能解释了低血糖发作风险相对较低的原因,且早晨给药有助于提高患者的依从性。作为格列齐特的常用剂型,缓释剂型适用于治疗成年2型糖尿病患者,当饮食、运动和体重减轻不足以恢复充分的代谢控制时。它可单独使用,或与二甲双胍、格列酮类、阿卡波糖或胰岛素联合使用,使用的一般原则与格列齐特经典剂型相同。